$64.2 Million is the total value of OUP Management Co., LLC's 15 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plcsponsored ads | $11,809,000 | -17.5% | 2,937,615 | 0.0% | 18.39% | -6.6% | |
| PMVP | PMV Pharmaceuticals, Inc. | $11,772,000 | -16.5% | 989,232 | 0.0% | 18.33% | -5.5% | |
| DICE Therapeutics Inc. | $10,884,000 | +30.7% | 536,693 | 0.0% | 16.95% | +47.9% | ||
| AVTE | Aerovate Therapeutics Inc. | $10,010,000 | +6.1% | 603,762 | 0.0% | 15.59% | +20.0% | |
| Sell | ionQ, Inc. | $5,970,000 | -1.1% | 1,177,597 | -14.5% | 9.30% | +12.0% | |
| CYT | Sell | Cyteir Therapeutics, Inc. | $4,742,000 | -35.9% | 2,469,572 | -0.2% | 7.38% | -27.5% |
| VOR | Vor Biopharma Inc. | $1,491,000 | -19.9% | 374,714 | 0.0% | 2.32% | -9.4% | |
| DTIL | Precision BioSciences, Inc. | $1,461,000 | -18.7% | 1,123,913 | 0.0% | 2.28% | -8.1% | |
| SELB | Selecta Biosciences, Inc. | $1,415,000 | +25.2% | 862,543 | 0.0% | 2.20% | +41.7% | |
| Sell | Evolv Technologies Holdings, Inc. | $1,383,000 | -67.1% | 652,475 | -58.8% | 2.15% | -62.8% | |
| GRPH | Graphite Bio | $1,288,000 | +15.3% | 406,308 | 0.0% | 2.01% | +30.5% | |
| LABP | Sell | Landos Biopharma, Inc. | $804,000 | -31.5% | 1,237,667 | -23.3% | 1.25% | -22.5% |
| eFFECTOR Therapeutics, Inc. | $587,000 | -59.7% | 1,025,697 | 0.0% | 0.91% | -54.4% | ||
| SPRO | Spero Therapeutics, Inc. | $498,000 | +169.2% | 249,070 | 0.0% | 0.78% | +203.9% | |
| FIXX | Homology Medicines, Inc. | $103,000 | -18.3% | 64,000 | 0.0% | 0.16% | -7.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-01
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Centessa Pharmaceuticals plc | 8 | Q3 2023 | 42.7% |
| Aerovate Therapeutics Inc. | 8 | Q3 2023 | 28.9% |
| PMV Pharmaceuticals, Inc. | 8 | Q3 2023 | 19.4% |
| Cyteir Therapeutics, Inc. | 8 | Q3 2023 | 15.7% |
| Vor Biopharma Inc. | 8 | Q3 2023 | 4.1% |
| Precision BioSciences, Inc. | 8 | Q3 2023 | 3.7% |
| Graphite Bio | 8 | Q3 2023 | 2.3% |
| eFFECTOR Therapeutics, Inc. | 8 | Q3 2023 | 3.8% |
| Selecta Biosciences, Inc. | 8 | Q3 2023 | 2.4% |
| Spero Therapeutics, Inc. | 8 | Q3 2023 | 1.8% |
View OUP Management Co., LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-24 |
| 13F-HR | 2023-02-02 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-19 |
| 13F-HR | 2022-05-04 |
| 13F-HR | 2022-02-03 |
View OUP Management Co., LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.